Market Research Logo

Plasma Fractionation Market by Product [IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor], Application (Immunology, Hematology, Critical Care, Rheumatology) End User (Hospital, Clinic, Academic Institute)-Global Forecast to 2024

Plasma Fractionation Market by Product [IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor], Application (Immunology, Hematology, Critical Care, Rheumatology) End User (Hospital, Clinic, Academic Institute)-Global Forecast to 2024

“Global plasma fractionation market is projected to grow at a CAGR of 6.6%.”
The global plasma fractionation market is projected to reach USD 34.9 billion by 2024 from USD 25.4 billion in 2019, at a CAGR of 6.6% during the forecast period. Growth in the plasma fractionation market can largely be attributed to factors such as the growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the increasing use of alpha-1-antitrypsin. However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market during the forecast period.

“By product, immunoglobulin market is expected to hold the largest share of the plasma fractionation market in 2019.”
The immunoglobulin segment is expected to dominate the plasma fractionation market during the forecast period. IVIg is the most extensively used plasma product across the globe, meant for the treatment of dermatomyositis, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), immune cytopenias, hypogammaglobinemia, primary antibody deficiency, vacuities, multiple sclerosis, asthma, and systemic lupus erythematosus, among other ailments. The growing prevalence of these and other target diseases, as a result, is the key driver of market growth.

“Factor VIII will dominate the coagulation factor concentrates market in 2019.”
The coagulation factor market is segmented into factor VIII, factor IX, Von Willebrand factor, prothrombin factor concentrates, fibrinogen concentrates, and factor XIII. Factor VIII segment is expected to hold the largest share in the coagulation factor concentrates market in 2019. This is attributed to the growth in geriatric population, rising number of hemophilic patients, increasing preference for prophylactic treatments for people suffering from hemophilia, and increasing diagnosis of hemophilia. In addition, the unavailability of advanced therapies for a majority of hemophilia patients in developing countries is also expected to drive this market.

“North America is expected to hold the largest share during the forecast period (2019-2024)”
North America is expected to dominate the plasma fractionation market during the forecast period. The demand for plasma products in North America is mainly driven by the increasing use of immunoglobulins in neurological and autoimmune diseases and the increasing use of prophylaxis treatments among diagnosed patients. The rising number of registered hemophilic patients (as illustrated in the table below) is also propelling the growth of this market. The growing number of hemophilic patients will increase the adoption of coagulation factors, which in turn will drive the market for plasma fractionation in North America.

A breakdown of supply-side primary participants is mentioned below:
By Company Type: Tier 1-38%, Tier 2-21%, and Tier 3-41%
By Designation: C-level-30%, Director Level-28%, Others-42%
By Region: North America-35%, Europe-25%, Asia Pacific-20%, Latin America-12%, Middle East and Africa-8%

Major players in the global plasma fractionation market include CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), BPL (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China).

Research Coverage:
The plasma fractionation market in this report is segmented by product, application, end user, and region. It provides detailed information regarding the major factors influencing the growth market (drivers, restraints, opportunities, and industry-specific challenges). The study tracks and analyzes competitive developments (such as partnerships, agreements, collaborations, mergers & acquisitions, product developments, geographical expansions, and R&D activities) and strategically profiles the key players and comprehensively analyzes their market shares and core competencies in the plasma fractionation market.

Reasons to buy this report:
From an insight perspective, this research report has focused on various levels of analysis—the market share analysis of top players in the global market, different product segments, as well on the regional levels, company profiles that comprise and discuss basic views on the competitive landscape; emerging and high-growth segments of the plasma fractionation market; high-growth regions; and market drivers, restraints, and opportunities. The report provides the latest statistics and industry trends, allowing buyers to identify high-growth product segments and potential customers and suppliers, hence driving revenue growth and profitability. The report provides insights on the following pointers:
Market Penetration: Comprehensive information on products offered by the top players in the global plasma fractionation market

Product Development/Innovation: Detailed insights on growth strategies, research & development activities, and product launches in the global plasma fractionation market

Market Development: Comprehensive information about lucrative emerging markets-the report analyzes the markets for plasma fractionation across regions

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global plasma fractionation market

Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the global plasma fractionation market


  • INTRODUCTION
    • OBJECTIVES OF THE STUDY
    • MARKET DEFINITION
    • SCOPE OF THE STUDY
      • MARKETS COVERED
      • YEARS CONSIDERED FOR THE STUDY
    • CURRENCY
    • STAKEHOLDERS
  • RESEARCH METHODOLOGY
    • RESEARCH APPROACH
      • SECONDARY SOURCES
      • PRIMARY SOURCES
    • MARKET SIZE ESTIMATION
      • BOTTOM-UP APPROACH
      • TOP-DOWN APPROACH
    • MARKET BREAKDOWN AND DATA TRIANGULATION
    • MARKET SHARE ESTIMATION
    • ASSUMPTIONS FOR THE STUDY
    • LIMITATIONS
  • EXECUTIVE SUMMARY
  • PREMIUM INSIGHTS
    • PLASMA FRACTIONATION MARKET OVERVIEW
    • GEOGRAPHICAL SNAPSHOT OF THE PLASMA FRACTIONATION MARKET
    • PLASMA FRACTIONATION MARKET: REGIONAL MIX
    • PLASMA FRACTIONATION MARKET, DEVELOPING COUNTRIES VS. DEVELOPED COUNTRIES
  • MARKET OVERVIEW
    • INTRODUCTION
    • MARKET DYNAMICS
      • Table PLASMA FRACTIONATION MARKET: IMPACT ANALYSIS
      • MARKET DRIVERS
        • Table ON-LABEL AND OFF-LABEL INDICATIONS OF IVIG
        • Table NUMBER OF CLINICAL STUDIES ON IMMUNOGLOBULINS, BY REGION, 2017
        • Table NUMBER OF PATIENTS TREATED FOR TOP 10 TARGET CONDITIONS IN THE UK (2015-16)
        • Table INCREASE IN GERIATRIC POPULATION FROM 2000 TO 2050 ACROSS THE GLOBE
        • Table NUMBER OF PLASMA COLLECTION CENTERS, BY COMPANY, 2018
      • MARKET RESTRAINTS
      • MARKET OPPORTUNITIES
        • Table NUMBER OF HEMOPHILIA PATIENTS IN DEVELOPED AND EMERGING COUNTRIES, 2016 VS. 2017
      • MARKET CHALLENGES
  • INDUSTRY INSIGHTS
    • INTRODUCTION
    • KEY INDUSTRY TRENDS
      • Table INCREASING CONSOLIDATION AND RISING ADOPTION OF SCIG ARE THE LEADING INDUSTRY TRENDS
      • FOCUS ON INCREASING FRACTIONATION CAPACITIES
        • Table FRACTIONATION CAPACITY EXPANSIONS BY MAJOR PLAYERS
      • NEW INDICATIONS FOR PLASMA PRODUCTS
      • RISING ADOPTION OF SCIG
      • INCREASING NUMBER OF FRACTIONATOR-OWNED PLASMA COLLECTION CENTERS
      • GROWING PLASMA PRODUCTS MARKET IN CHINA
        • Table PER CAPITA CONSUMPTION OF IVIG AND ALBUMIN, BY COUNTRY (2014)
        • Table CHINA: TOP PLAYERS IN THE PLASMA FRACTIONATION MARKET, 2018
        • Table MAJOR LOCAL PLAYERS IN CHINA
      • INCREASING FOCUS OF PLASMA FRACTIONATORS TOWARDS MANUFACTURING AND DEVELOPING RECOMBINANT FACTORS
        • Table REGIONAL IMPACT ANALYSIS OF RECOMBINANT FACTORS ON PLASMA-DERIVED PRODUCTS
    • PORTER'S FIVE FORCES
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTES
      • BARGAINING POWER OF SUPPLIERS
      • BARGAINING POWER OF BUYERS
      • INTENSITY OF COMPETITIVE RIVALRY
    • VENDOR BENCHMARKING
      • PRODUCT PORTFOLIO ANALYSIS: PLASMA FRACTIONATION MARKET
      • NO. OF PLASMA COLLECTION CENTERS AND FRACTIONATION CAPACITIES, BY KEY PLAYER
      • BUSINESS PRESENCE OF KEY PLAYERS IN THE VALUE CHAIN
    • PRICING ANALYSIS
      • Table AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS, BY PLAYER (2018)
      • Table AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS, BY REGION (2018)
  • PLASMA FRACTIONATION MARKET, BY PRODUCT
    • INTRODUCTION
      • Table PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
    • IMMUNOGLOBULINS
      • Table IVIG VS. SCIG THERAPY
      • Table IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
      • Table IMMUNOGLOBULINS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
      • INTRAVENOUS IMMUNOGLOBULINS
        • Table INTRAVENOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
        • Table INTRAVENOUS IMMUNOGLOBULINS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
        • Table INTRAVENOUS IMMUNOGLOBULINS MARKET, BY REGION, 2017–2024 (METRIC TONS)
      • SUBCUTANEOUS IMMUNOGLOBULINS
        • Table SUBCUTANEOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
        • Table SUBCUTANEOUS IMMUNOGLOBULINS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
        • Table SUBCUTANEOUS IMMUNOGLOBULINS MARKET, BY REGION, 2017–2024 (METRIC TONS)
      • OTHER IMMUNOGLOBULINS
        • Table OTHER IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
        • Table OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
        • Table OTHER IMMUNOGLOBULINS MARKET, BY REGION, 2017–2024 (MILLION INTERNATIONAL UNITS)
    • COAGULATION FACTOR CONCENTRATES
      • Table COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
      • Table COAGULATION FACTOR CONCENTRATES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
      • FACTOR VIII
        • Table FACTOR VIII OFFERED BY KEY MARKET PLAYERS
        • Table FACTOR VIII MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
        • Table FACTOR VIII MARKET, BY REGION, 2017–2024 (MILLION INTERNATIONAL UNITS)
      • FACTOR IX
        • Table FACTOR IX OFFERED BY KEY MARKET PLAYERS
        • Table FACTOR IX MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
      • VON WILLEBRAND FACTOR
        • Table VON WILLEBRAND FACTOR OFFERED BY KEY MARKET PLAYERS
        • Table VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
      • PROTHROMBIN COMPLEX CONCENTRATE
        • Table PROTHROMBIN COMPLEX CONCENTRATES OFFERED BY KEY MARKET PLAYERS
        • Table PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
      • FIBRINOGEN CONCENTRATES
        • Table FIBRINOGEN CONCENTRATES OFFERED BY KEY MARKET PLAYERS
        • Table FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
      • FACTOR XIII
        • Table FACTOR XIII OFFERED BY KEY MARKET PLAYERS
        • Table FACTOR XIII MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
    • ALBUMIN
      • WIDE DEMAND FOR ALBUMIN AS AN ANTIOXIDANT AND VOLUME EXPANDER WILL DRIVER MARKET GROWTH
        • Table ALBUMIN OFFERED BY KEY MARKET PLAYERS
        • Table ALBUMIN MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
        • Table GLOBAL ALBUMIN MARKET, BY REGION, 2017–2024 (METRIC TONS)
    • PROTEASE INHIBITORS
      • INCREASING GLOBAL DISEASE BURDEN WILL DRIVE DEMAND FOR PROTEASE INHIBITORS
        • Table PROTEASE INHIBITORS OFFERED BY KEY MARKET PLAYERS
        • Table PROTEASE INHIBITORS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
    • OTHER PRODUCTS
      • Table OTHER PRODUCTS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
  • PLASMA FRACTIONATION MARKET, BY APPLICATION
    • INTRODUCTION
      • Table PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
    • NEUROLOGY
      • RISING PREVALENCE OF MAJOR AGE-RELATED NEUROLOGICAL DISORDERS TO DRIVE THIS MARKET
        • Table NUMBER OF DALYS FOR NEUROLOGICAL DISORDERS AND THE PERCENTAGE OF DALYS PROJECTED FOR 2005, 2015, AND 2030
        • Table PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN NEUROLOGY
        • Table PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2017–2024 (USD MILLION)
    • IMMUNOLOGY
      • INCREASING PREVALENCE OF IMMUNODEFICIENCY DISORDERS AMONG CHILDREN AND ADULTS TO DRIVE THE GROWTH OF THIS MARKET
        • Table LIST OF FDA-APPROVED INDICATIONS FOR IMMUNOGLOBULINS IN IMMUNOLOGY
        • Table PRIMARY IMMUNODEFICIENCY DISEASE, BY TYPE
        • Table PREVALENCE OF PRIMARY IMMUNODEFICIENCY DISEASE, BY REGION, 2013 VS. 2015
        • Table PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN IMMUNOLOGY
        • Table PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2017–2024 (USD MILLION)
    • HEMATOLOGY
      • GROWTH IN THE NUMBER OF HEMOPHILIA PATIENTS TO DRIVE THE DEMAND FOR COAGULATION FACTOR CONCENTRATES AND IMMUNOGLOBULINS
        • Table NUMBER OF HEMOPHILIA PATIENTS (2012–2017)
        • Table PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN HEMATOLOGY
        • Table PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2017–2024 (USD MILLION)
    • CRITICAL CARE
      • INCREASING OFF-LABEL USE OF ALBUMIN AND RISING USE OF ANTICOAGULANTS TO DRIVE THE DEMAND FOR PLASMA-DERIVED CRITICAL CARE PRODUCTS
        • Table PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN CRITICAL CARE
        • Table PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2017–2024 (USD MILLION)
    • PULMONOLOGY
      • RISING PREVALENCE OF ALPHA-1 ANTITRYPSIN DEFICIENCY AND COPD TO DRIVE THE PLASMA FRACTIONATION MARKET FOR PULMONOLOGY
        • Table PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN PULMONOLOGY
        • Table PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2017–2024 (USD MILLION)
    • HEMATO-ONCOLOGY
      • RISING NUMBER OF BLOOD CANCER PATIENTS TO DRIVE THE DEMAND FOR PLASMA-DERIVED PRODUCTS IN HEMATO-ONCOLOGY
        • Table INCIDENCE OF LEUKEMIA, MULTIPLE MYELOMA, AND HODGKIN LYMPHOMA, BY REGION, 2012 VS. 2015 VS. 2018
        • Table PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN HEMATO-ONCOLOGY
        • Table PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2017–2024 (USD MILLION)
    • RHEUMATOLOGY
      • INCREASING PREVALENCE OF RHEUMATIC CONDITIONS TO DRIVE THE PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY
        • Table PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2017–2024 (USD MILLION)
    • OTHER APPLICATIONS
      • Table PLASMA-DERIVED PRODUCTS FOR OTHER APPLICATIONS
      • Table PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
  • PLASMA FRACTIONATION MARKET, BY END USER
    • INTRODUCTION
      • Table PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
    • HOSPITALS & CLINICS
      • IMPROVING HEALTHCARE INFRASTRUCTURE AND GROWTH IN THE NUMBER OF HOSPITALS & CLINICS—KEY FACTORS DRIVING GROWTH
        • Table PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2017–2024 (USD MILLION)
    • CLINICAL RESEARCH LABORATORIES
      • INCREASING NUMBER OF CLINICAL STUDIES ON NEW THERAPEUTIC INDICATIONS FOR PLASMA-DERIVED PRODUCTS TO DRIVE THE MARKET FOR CLINICAL RESEARCH LABORATORIES
        • Table CLINICAL STUDIES ON ALBUMIN & IMMUNOGLOBULIN (2017)
        • Table PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2017–2024 (USD MILLION)
    • ACADEMIC INSTITUTES
      • INCREASING BASIC MEDICAL RESEARCH ACTIVITIES AND GROWING DEMAND FOR NEW DRUG MOLECULES TO DRIVE THE DEMAND FOR PLASMA PRODUCTS IN ACADEMIC INSTITUTES
        • Table PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2017–2024 (USD MILLION)
  • PLASMA FRACTIONATION MARKET, BY REGION
    • INTRODUCTION
      • Table REGIONAL DISTRIBUTION OF PLASMA FRACTIONATION PLANTS AND PLASMA THROUGHPUT, BY REGION, 2014
      • Table PLASMA FRACTIONATION MARKET, BY REGION, 2017–2024 (USD MILLION)
    • NORTH AMERICA
      • Table NORTH AMERICA: HEMOPHILIA PATIENTS, 2013 VS. 2017
      • Table TRANSFER OF PLASMA FROM US TO OTHER REGIONS, 2014
      • Table NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
      • Table NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
      • Table NORTH AMERICA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
      • Table NORTH AMERICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
      • Table NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
      • Table NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • US
        • Table US: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table US: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table US: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table US: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table US: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table US: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • CANADA
        • Table CANADA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table CANADA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table CANADA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table CANADA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table CANADA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table CANADA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
    • EUROPE
      • Table EUROPE: PLASMA COLLECTION, 2007–2016
      • Table PLASMA FRACTIONATION PLANTS IN EUROPE (2017)
      • Table EUROPE: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
      • Table EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
      • Table EUROPE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
      • Table EUROPE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
      • Table EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
      • Table EUROPE: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • GERMANY
        • Table GERMANY: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table GERMANY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table GERMANY: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table GERMANY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table GERMANY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table GERMANY: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • FRANCE
        • Table NUMBER OF PEOPLE WITH BLEEDING DISORDERS IN FRANCE, 2012–2017
        • Table FRANCE: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table FRANCE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table FRANCE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table FRANCE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table FRANCE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table FRANCE: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • ITALY
        • Table ITALY: NUMBER OF BLOOD DONATIONS, 2011 VS. 2013
        • Table PRODUCTION OF PLASMA PRODUCTS IN ITALY (2013, 2018-E, & 2023-E)
        • Table ITALY: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table ITALY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table ITALY: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table ITALY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table ITALY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table ITALY: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • SPAIN
        • Table SPAIN: KEY MACROINDICATORS FOR THE PLASMS FRACTIONATION MARKET
        • Table SPAIN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table SPAIN: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table SPAIN: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table SPAIN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table SPAIN: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • UK
        • Table USAGE OF IMMUNOGLOBULINS
        • Table ESTIMATED NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS IN THE UK, 2012–2016
        • Table VOLUME OF IMMUNOGLOBULINS USED FOR THE TOP 5 DIAGNOSES (2016)
        • Table UK: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table UK: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table UK: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table UK: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table UK: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table UK: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • REST OF EUROPE
        • Table TOTAL NUMBER OF HEMOPHILIA PATIENTS IN REST OF EUROPE: 2012–2017
        • Table ROE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table ROE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table ROE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table ROE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table ROE: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
    • ASIA PACIFIC
      • Table ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
      • Table ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
      • Table ASIA PACIFIC: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
      • Table ASIA PACIFIC: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
      • Table ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
      • Table ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • CHINA
        • Table CHINA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table CHINA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table CHINA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table CHINA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table CHINA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table CHINA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • JAPAN
        • Table MEAN PER CAPITA FACTOR VIII AND IX USE IN JAPAN, 2014 VS. 2017 (IN IU/TOTAL POPULATION)
        • Table PATIENTS WITH BLEEDING DISORDERS IN JAPAN, 2014 VS. 2017
        • Table JAPAN: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table JAPAN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table JAPAN: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table JAPAN: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table JAPAN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table JAPAN: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • AUSTRALIA
        • Table TOTAL IG (GRAMS) USED IN AUSTRALIA, 2006–2015
        • Table AUSTRALIAN GOVERNMENT FUNDING FOR THE SUPPLY OF BLOOD AND BLOOD PRODUCTS, 2008–2017 (USD MILLION)
        • Table AUSTRALIA: BLOOD SECTOR OVERVIEW (2017)
        • Table AUSTRALIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table AUSTRALIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table AUSTRALIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table AUSTRALIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table AUSTRALIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table AUSTRALIA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • INDIA
        • Table INDIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS, 2012–2016
        • Table INDIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table INDIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table INDIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table INDIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table INDIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table INDIA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • VIETNAM
        • Table VIETNAM: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table VIETNAM: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table VIETNAM: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table VIETNAM: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table VIETNAM: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table VIETNAM: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • INDONESIA
        • Table INDONESIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table INDONESIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table INDONESIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table INDONESIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table INDONESIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table INDONESIA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • MALAYSIA
        • Table MALAYSIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS, 2012–2017
        • Table MALAYSIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table MALAYSIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table MALAYSIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table MALAYSIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table MALAYSIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table MALAYSIA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • REST OF ASIA PACIFIC
        • Table REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table REST OF ASIA PACIFIC: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table REST OF ASIA PACIFIC: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
    • LATIN AMERICA
      • IMPLEMENTATION OF GOVERNMENT INITIATIVES TO PROMOTE HEALTHCARE SERVICES, RISING GERIATRIC POPULATION, AND INCREASING INCIDENCE OF BLEEDING DISORDERS TO DRIVE MARKET GROWTH IN LATIN AMERICA
        • Table BRAZIL: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table MEXICO: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table LATIN AMERICA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table LATIN AMERICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
    • MIDDLE EAST & AFRICA
      • Table HEMOPHILIA PATIENTS IN THE MIDDLE EAST AND AFRICA, 2012–2017
      • Table PER CAPITA CONSUMPTION OF FACTOR IX AND VIII (IU/TOTAL POPULATION) IN SOUTH AFRICA, SAUDI ARABIA, AND IRAQ, 2012–2017
      • Table MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
      • Table MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
      • Table MIDDLE EAST & AFRICA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
      • Table MIDDLE EAST & AFRICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
      • Table MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
      • Table MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • TURKEY
        • Table TURKEY: DEMOGRAPHIC INDICATORS
        • Table TURKEY: REPORTED CASES OF BLOOD DISORDERS, 2012 VS. 2014
        • Table TURKEY: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table TURKEY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table TURKEY: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table TURKEY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table TURKEY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table TURKEY: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • SAUDI ARABIA
        • Table ESTIMATED INCIDENCE AND PREVALENCE OF CID, SCID, AND MHC II DEFICIENCY IN CHILDREN IN SAUDI ARABIA
        • Table PER CAPITA CONSUMPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) AND ALBUMIN (2015/2016)
        • Table SAUDI ARABIA: BLOOD DISORDER CASES, BY TYPE, 2014 VS. 2016
        • Table SAUDI ARABIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table SAUDI ARABIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table SAUDI ARABIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • EGYPT
        • Table EGYPT: BLOOD DISORDER CASES, BY TYPE, 2014–2017
        • Table EGYPT: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table EGYPT: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table EGYPT: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table EGYPT: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table EGYPT: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table EGYPT: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • UAE
        • Table UAE: GROWTH IN THE NUMBER OF BLOOD DONORS
        • Table UAE: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
        • Table UAE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table UAE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table UAE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table UAE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table UAE: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
      • REST OF MIDDLE EAST AND AFRICA
        • Table HEMOPHILIA PATIENTS IN THE REST OF MIDDLE EAST AND AFRICA, 2012 VS. 2017
        • Table PER CAPITA CONSUMPTION OF FACTOR IX AND VIII IN SOUTH AFRICA AND QATAR (IU/TOTAL POPULATION), 2013 VS. 2017
        • Table ROMEA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
        • Table ROMEA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table ROMEA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
        • Table ROMEA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
        • Table ROMEA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
  • COMPETITIVE LANDSCAPE
    • OVERVIEW
      • Table GROWTH STRATEGY MATRIX
    • MARKET SHARE ANALYSIS
      • MARKET SHARE ANALYSIS, BY PRODUCT,2018
      • MARKET SHARE ANALYSIS, BY REGION,2018
    • COMPETITIVE LEADERSHIP MAPPING
      • VISIONARY LEADERS
      • INNOVATORS
      • DYNAMIC DIFFERENTIATORS
      • EMERGING COMPANIES
    • COMPETITIVE SCENARIO AND TRENDS
      • PRODUCT LAUNCHES/APPROVALS
        • Table PRODUCT LAUNCHES/APPROVALS, JANUARY 2016 TO APRIL 2019
      • EXPANSIONS
        • Table EXPANSIONS, JANUARY 2016 TO APRIL 2019
      • ACQUISITIONS
        • Table ACQUISITIONS, JANUARY 2016 TO APRIL 2019
      • AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS
        • Table AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS, JANUARY 2016 TO APRIL 2019
  • COMPANY PROFILES
    • CSL
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • SWOT ANALYSIS
      • MNM VIEW
    • GRIFOLS
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • SWOT ANALYSIS
      • MNM VIEW
    • SHIRE
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • SWOT ANALYSIS
      • MNM VIEW
    • OCTAPHARMA
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • SWOT ANALYSIS
      • MNM ANALYSIS
    • KEDRION
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • SWOT ANALYSIS
      • MNM VIEW
    • LFB
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • BIOTEST
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • SANQUIN
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • MNM VIEW
    • CHINA BIOLOGIC PRODUCTS
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • BIO PRODUCTS LABORATORY (BPL)
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • JAPAN BLOOD PRODUCTS ORGANIZATION
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • MNM VIEW
    • GC PHARMA (GREEN CROSS CORPORATION)
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • SHANGHAI RAAS BLOOD PRODUCTS
      • BUSINESS OVERVIEW
      • PRODUCTS OFFERED
      • RECENT DEVELOPMENTS
      • MNM VIEW
  • APPENDIX
    • INSIGHTS OF INDUSTRY EXPERTS
    • DISCUSSION GUIDE
    • KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
    • AVAILABLE CUSTOMIZATION
    • RELATED REPORT
    • AUTHOR DETAILS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report